Regulatory Approval

ECO Animal Health Group plc

(AIM: EAH)

ECO RECEIVES MARKETING AUTHORISATION FOR AIVLOSIN® FOR CHICKENS LAYING EGGS FOR HUMAN CONSUMPTION IN INDIA

ECO Animal Health Group plc (the “Group”) is pleased to announce that its subsidiary ECO Animal Health Limited (ECO) has received a marketing authorisation from the Central Drugs Standard Control Organisation, Ministry of Health & Family Welfare of the Government of India for the use of Aivlosin® 625 mg/g water soluble granules in chickens laying eggs for human consumption.

This approval allows ECO to start selling Aivlosin® in India for the medication of drinking water for the treatment of infections caused by Mycoplasma in poultry laying eggs for human consumption, with a zero day drug withdrawal period for eggs.

Aivlosin^®, ECO’s patented antimicrobial, is used under veterinary prescription for the treatment of a variety of economically important respiratory and enteric (gut) diseases in poultry and pigs.

Peter Lawrence, Non-Executive Chairman of ECO Animal Health Group plc, commented “India is ranked second with just over 5 per cent of the world’s laying birds and although the market is somewhat fragmented, we expect this to change in the future. This latest approval demonstrates ECO’s continued progress in rolling out this indication for commercial layers”.

The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). Upon the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

Contacts:

ECO Animal Health Group plc

Peter Lawrence		020 8336 6190
Marc Loomes		020 8447 6906
Spiro Financial
Anthony Spiro		020 8336 6196
N+1 Singer (Nominated Adviser)		020 7496 3000
Mark Taylor, Brough Ransom
Peel Hunt LLP (Joint Broker)
James Steel, Dr Christopher Golden		020 7418 8900

ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for animals. Our products for these global growth markets promote well-being. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders

View source version on businesswire.com: https://www.businesswire.com/news/home/20190304005702/en/

Copyright Business Wire 2019